Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + apatinib + irinotecan liposome
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of adebrelimab, a PD-L1 inhibitor; apatinib, a VEGFR2 tyrosine kinase inhibitor; and a liposomal formulation of irinotecan, a topoisomerase I inhibitor. It is currently being evaluated in a Phase Ib/II clinical trial (sponsored by Xianglin Yuan) as a second-line treatment for patients with advanced gastric cancer, including those who have previously progressed on immune checkpoint inhibitor therapy. The regimen is designed to leverage the anti-angiogenic effects of apatinib to potentially improve drug delivery and modulate the tumor microenvironment, the cytotoxic activity of liposomal irinotecan to induce tumor cell death, and the immunomodulatory action of adebrelimab to restore the anti-tumor immune response.
- Brand names
- Duoenda
- Other names
- Adebrelimab + Apatinib + Irinotecan liposomeAdebrelimab + Apatinib + Lrinotecan liposome
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on adebrelimab + apatinib + irinotecan liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + apatinib + irinotecan liposome.